Exhibit 7.3

DEFINITIVE SHARE PURCHASE AGREEMENT (SPA) BY AND AMONG MYRXWALLET PRANA, PVT. L TO. an India register company (..AcquIrer") (a Subsi iary of MYRXWALLET f \ ORTH AMERICA CORPORATION) AND OAH THERAPEUTICS PVT. LTD , an India register company ("Sell r") June 17, 2025 MyRxWallet Prana Private Limited A subsjdiery of MyRxWiLllet North Amettea Coq,oration Un iled States of Am � rlea

OEFINJTIVE SHARE PURCHASE AGREEMENT This D finltive Share Purchase Agroornanl (th s "A,greemem•J Is ente - 1ed Into as of June 17, 2025 by and amo g MyRxWanet Pratia Pflvale Limited . a company incorporated under the laws of lnd · B pursuant to the Compan i es Act, 2013 (the 'Acquirer"}. a d a majorlty - owr)ad subsidiary of 1yRxWallet North Am rfca Corp � allor, ( th � "A.cq ire r Parenf'), and Noah Th rapeutlcs Priva e ti m • ed, a company imxxporated urtder the laws of India (the •s ner"). Tho Acq lror and lh8 Saller are hereinafter collectively referred to as the "Parties 0 and indi VR:lually as a "Party ," RECITALS � EREAS . the Seifer i s the legal end beneficia l owner of 100% of t ho issood and outstandiTig equity shares of Noah Th rapeutlcs Priv a te Limited ( the "Company") ; WHEREAS, the Acqulrer desires to purchaoo, and the Sel ler de si re6 to sell, seventy percent (70%) of the equity shares of the Company, on t he tern,s and subj ect to the condilions set forth in this Agreement (1he 'Transaction··); WHEREAS, the Parties desire to set forth the t8ITTIS and conditions upon which such sale and purchaso shall be con$ummated; NOW , EREFORE, in cons·deration of the mutual covenants and agrooments oonlained herefn an d fo r other good and val able COl'ls.l ra Ion, the rec eipt and sufficiency of which are hornby acknowledged, U,e Parties agree as follows: G:) STRATEGIC BENEFITS OF ACQUIRING NOAH THERAPEUTICS, Contract Research Organization (CRO) Acquiring Noah , Contract Researcti Organization (CRO). provldos MyRxWallet lh a transrormat ive oppo,tunity to optimize drug d&volopm t enhance innovation , and seCtJre long - term competitive advantage . This ac ul J lion scrategicalfy aligns cl i nica l development of MyRxVva Ue t � ' th business objectives, eoob ing pha,ma and biotQch to increase efficiency, p otect tor � assets , and lead in an illc roaslngly oomplex global R&0 environment. 1 . Speed to Market • Acoelerated Drng Developmant: Noah has established processes, global site networks, and expe n¢e personne l , enabling faster cun · ca l trial execution . • Reg latory Expenise: Noah btlng s trong regulato ry know - ho \ v, he plng Mvlgare complex approval processes efficiently across global markets . MyRxWallet Prana Private Limited A $Ub ldlar � of MyRxWellet North Amerre:s Corporation United State,s o Aniorica

2. Cost Efficiency hlft from fixed intetnal R&D costs to • Reduced Flx9d Cost : oal \ allows MyRxWalt l t a more variable model � ith better scalab · lity. • Opera • al Synergies: Integratlon may reduoe dupl.cation In pr - oject management, data mindling, 81 \ d administrative tasks. 3. Increased Control and Customiza n • Alignment of Priorities : A rulty CN ned CRO \ II prlorill:t:e i nlemel pipel i nes, align timehnes, and 9hare strategic goals . • Tailored Capabilities : Ernibles customization of SOPs, l&ehr ology platforms, and trief d lgns to mea sped ,c drug dev Joprnent strateg · es . 4. Cotnpatl ve A antaga • V rt e I I ntegration : Control over tile fuII R&D cnain from discovery to commercl.allzatlon ca create a susfainabto com tltlve edge . • Diffe - re tiated Off rings : Noah could beoome a profit center by offering seNices to external clients wh i le s \ Jpporting interna.J pipelines. 5. Access to Talen and 1 frastructure • Global Reach and Networks : Acquiring Noah l nc lud � r;1coess to g(obaJ trjaf sites, nvestlga o r s , and patlec,t popula · ons . • Experienoed Wo � :dorce : Offers i mme<l i ate access to a trained workforoe, eluding clinical trial managers . blo - .4>t � tI$t ic l l"IS, <lata managers . and regulatory experts. 6. Data and IP Cor trol • Ownership or Trial Oat.a ; Ensures l>etter co trol over cllnlcal data , reducing risk of data loss , leakage, or misuse . , IP SeCtJrity : Reduoes risk of nteJla toal roperty leakage that can occu whtil wor I n g with externaJ vendors . 7. Scalablllty and F � xlbilily • Scslabl OperatiollS : Noah infrastructure can support both er;Jrly - Cage and late - stage trials across multiple geograp los a d dlcalions . • Thorap ulfc Expertise : Nqc1h has specialized experiencB In key therapeutic areas, whicti can b � l eversged across e development portfolio . 8. Stra egio PO$ition i ng for Innovation • New Tech o ogy lntegra n : MyRxWalle can deploy digi al lleatth tools. AJ/ML In dets a n alysis , &Centralized tria l models , and MyRxWall l - E H R olu i s . MyRxWallet Prana Private Limited A subsidiary of MyRxW llct North America Corporation United Stabts of America

• Real - \ , 'orld Evidence {RW ) Capabir ies � Noah enables tighter lntegre � on o resl Nortd data into clinical development NOW, HEREFORE, in consideration of the repres, .ntatlons , w rrantie , and covenants h reiri oorilained, and for other good and valuable conslde lions, the rece· and sufficiency o which are h reby acknowledged , the paroes hereto agree as follO \ vs: ARTICLE I CERTAJN OEFINlTIONS 1. Certain Definitions: (a) The follo ving terms, w,en used in 1tlls Agreement, ehRU heve the respective meanings ascribed to them be l ow: 'ACTION" mean any c m, aotion, suit, inqu i ry, hearing lnvostlgauon or other proc 9d r.g, ,. AF IUA mea11s, with respect to a Person, allY other Per on that. directly or indirectly, through one or more lnterrnedi.aries, Controls . is co trorled by or Is under oommon Control with, suet, Pe SOfl, or pYrposes of this de fi · n tIon , 'CONTROL• (incJIJding. with correlative meanings, the terms •co troll&d by" and under common Control with ) m ans lhe posses 'on, directly or indrrectly, of the pov to dJrect Of cause he drre • n of ttle management ƒ ' policies of a Person. whether through the ownersh i p of stock, as trustee or executor, by Contract r credit arrangement or otherwise . "ACQUIRER" has ti rr Bar1.ir19 et forth in e preamble hereto. AGRE ENT'' has the aanir"lg set forth in the preamble her - eto . 'ANC � LLARY AGREEMENTS" means the BIii of SaJe and the IP Assignment. •ASSETS" l \ as he meaning se forth in Section 2 . 1 . BUSINESS DAY" means any day other than Saturday, Sunday or any day on which ba ks in as Vegas, Nevada are requJred or authoriz.ed to be closed. "CLOSING ha ttle m aning set forttl in Section 3.1, "CLOSING DATE" h13s the meaning se forth in Section 3.1. MyRxWaJlet Prana Private Limited A subsidiary of MyR'x.W llot North America Corporation United States of America

� CONTRACT means any a reatnenl, lease, debenture, note, bond, cvld81 \ C8 of Ind btoo.n ss , rnortgage, indenture, seoori y agreement , optlol' ot oU,er contract or oommitment (whettler wri en or oral). •EXCLUDED ASSETS" ha the meaning set forth in Section 2,3 . ·excLUDED L IABILITIES'' has ti" \ m , ng set forth in Section 2 . 3. GAAP• means United States generally accopted a<: 01 . mUng principles as in effect fro time to time, consrs - tently applied throughout the specified period and all prior oompara e periods . "GOVERN ENT AL ENTITY.. means any government or political subd j vislon thereo , wh8 her orelgl' \ r dorries · c , federal, state. proviocial. county, loca l, munic · paJ or regional or any other governmental en ty , any agency, authority depanmcnt, divis · on ƒ ' Instrumentality of any suet govemtnenl, political subdivision or oU - .er goOJornmenta l en ity, any court. arbitral trib \ Jnal or arbi rator , and any nongovarnm nuil regulating body, o thee nt thi;lt the rules, regulations or ord rs of ucti body ave the force of Law . "INDEBTED ES$" means, as to any Person : () a I obllg ions, whether or no con ngant. of su!;'h Person for borrow&d mone � (Including, wittiout li mitation, rclmbursemen and all other obligations v U, respecl t o surety bonds , letters of croolt and bankers' acceptancas, whether or not matured), (ii} all obligalioos of Sl>Ch Person evidenced by not � . bonds, deben res, capctaJized leases ƒ ' i rnilar instruments, (iii} all obligatlons of such Person represontlng the baJance of dererred purchas price of coperty o se r vices . ( iv) all i t r, st f ale and c1 . .arrency swaps, caps. ooJlars and slrn � $r agr � ments or hedging dovlc9S under w ich payments are obligat8d to be made by su - ch Person. wheth petlodlcally or upon the happening of a contln ncy, (v) all ifldebledness created or arlslt' \ g unde ar1y conditional saJ or other tit e Mlenllor1 Contract with respect to properly cqulred by such Pernon (even though the rlgh sand remedies of the - sol r or le nde r under such Contract i n the ev � rit of dafauf are lrmited to repossession or sale or such property), (vi) alt Jndebtedness secured l>y any Lian on any property or asset owned Of held by such Person regardless of whether the indebtedness secured th reby stt.a II have been assumed by such Perso or is noll - recourse to tho crodlt of such Person, an (vii) alJ indcbt dness referred to · n clauses {i) th11 9h ('JI) bove o any other Perso that s 9u ranleed , directly or i irectly, by suet Person. • JNTELLECTUAL PROPERTY" means : all (i) dlsooveries and inven ons (whetllor pat nta le or unpatenta le and ether oc r)t>l reduced to pra · ce}, all ,mprovtimenls - thereto , nd all un · ed States , international, and oreign patents. pate t applic tions (eith er led or in preparatioo for nl i ng). pate nt discios res and statutory inv ntion registra ions, incfud l l'lg all r · ssuanees. divisions. continuations , tin.uations in pert ex cnsions and raexa ir,ations thereof, all rig ts therein provided by intematio I treaties o oo VE?ntions , {ii) trademarks. service marks . trade dre s, logos . trade names. corpcrata mes , and other source den If a s (whether or not registered) including all common law igh s . all reg i strations end applictJtions for registration (either fl or in p r eparation for - rmll9) thereof, all rights therein provided by in tematlonal traa • $ or conve n · ons, and all rnoQWals o any o the foregoing, (iJI) all copyrightable worts an d copy . hls ( Nhether or not reglstcrod) , al regiStretions an d appllcatlons for registration ther � o f, � , • hts here i n prov i ded by Jnlem tional treaties or conv n ns, and all data and documentatio relatin g th • elo, ( 1 v} confidential and proprietary information, trade MyRxWa ll et Prana Private Limited A su � ,dlar}' of MyRxWallet North America Corporation Unft cl Staten, of America

saCtets, know•how {whether pa antable or nonpatentablo and whether or not reduced to practice), processe a tech iques, research and development informatlol \ lnolud"il"9 patent andlor copyright searches conducted by Seller and/or any tl'lird party. ideas, tcchnJcal data, designs, drawings and s � cifications, (v) Software, (vi) coded values, forma s, data and historic I or current databasos. whether or not copyrightable, (Vii) domain names, Int m � ebsites or identities us d or held for use by th Sel t , (vi"') otfler proprl tary rights retatil"9 to any of lhe fofi going (inciuding without lim tat on riy and an associated goodwill and remedies agait,s infringements thereof ood ,ights o protection of an interest therein under the l � v,s of all jurisdictions). and (ix) copies and tangible embodiments of any of the forogolng. "IP ASSIGNMENT' has U,e meaning set forth in Section J.2(b). "KNOWLEDGE'' mean tile a � tual or constru · va knowledge after duo inquiry of any curre t officar or manager of the Seller. � LAWS' means all laws, sta1u � s. rules, reguJatlol \ s, 0rdir1aoces and other prono noemant � having the effect of law of e un · teo States, any foro gn co1111try or any domestic or foreign state, county, city or otfler political subdlvl Ion or of a y Govemmentat En tty. "LIABILITY" means all Indebtedness. obllgatlons arid other Liabilities of a Per$on, whether � bsolute, accr � - eo. conting nt, ri � ed or o herwise, and vhethar due or to become - due (incl ding for Taxes). "LIEN" means any mart age, pledge, assessment, s � curity interest, lease, II n, adverse claim. levy, charge or other encumbranc of any kind . whetfler voruntary or lnvo f untary (irtcllJd i ng any condition sal Contr:.ict, title reten• Contract ot C - ontl"flct oomm , tting to grant a y of the foregoing) . oss � means all damages , fir � e , fees, penalties, doficlencles, losses and expenses {including without lfmltallon, all in ere - st, court oosts, foes and expenses of attorneys accountants alld other experts or otho expenses of litigation or other proceed rigs or of any c; im, defauI or assessment). "MATERIAL ADV RSE EFFECT' means any mate lal adverse effect on the condition, operations, buslne , pros.pects or results of sales of the Selle. PROVIDED HOWEVE:R, tha any adverse effect arisJng out of 0t resulting from the entering into of this Agreement or the consummation of tt a transactions contemplated h reby, shall be excluded in de rmlnlng vh u,e a Materi I Adverse Effect has occurt8d. 'OROER means any wri judg ent, d ree, injunction or si !Jar ord8' o ijf' \ Y Gover me tal En · y (in each case /he her prelim · nary or final). ·•p RSON' means any individual. part.n rship , I mited liability co pan>·· ocrporation, association. joint stock company, trust. estate, joint ve ture, un c;orpora ed organization, Governmental f:ntl or any other eJltity of any kind . •PURCHASE PRICE" has the meaning set f; th In Section 2.1 . MyRxWa ll et Prana Privat Limited A subsidiary of MyRxWallet Nor1h Amerle:1 Corporation Unrted State$ of America

·REPRESENTATIV S means, with resp ct to any Person, the directors, officers, manag � rs, employees Ź counsel , acoountanls and othei - autho.rlzed representatives of such Person . SEUER" has the meaning set forth in e preamble hereto . 0 $0flWARE' mea s all computer software, Including source cod , obj ct code, machine - readable code HTML or other martcu language , program listlng , comments, user in erfaoos, met'lus - , buttons and Icons, web applica · oos and a l l files , data , anu.als , design notes, research and dev loprnent documents , and o ,er i ems and document lion related thereto or assoc i led ttlerewith . "SOLVENT" me.ans, wi h rcspgct to tne Serler, tha (a) the SelJ r can pay its liab " litl , as they mature in tfle nonnal oourae of bus · ness, and (b} ,a fair va ue of the assets of the Seller is greater han he total amount of Liabllitles of lhe Seirer . "TAX RETURNS" ar 'l s all re:t1rllS and reports (Incl ing elections, claims, declarations , dlsclosur'eS, schedules. estlmat , computations and information returns) requ red to be ppl i ed lo a tax authority In any Jutisdicoon relatlng to Taxes . "TAXES" meal' \ s a � I federal, stat , local and foreign irtcome, profits , franchise, license. social securtty , transfer. rogls atlon , es · mated , gross rec i pts, enviroomental, cu.stoms duty, ca aJ stock, EtVer nee . stamp , pay r oll , sales , employment , un mployment , disability, use, property , withholding. excise, production, value add d oocupancy and other tax , duties or assessment or any nature whatsoove , together vith all interes t pena · l es , fines and addllioos to ta)( imposed witl'l res � t to $ - \ Jch amounts and any Interest in respec of such pena lt ies and additions to tax. "THIRD - PARTY CLAI "has the mean i ng se t fi h in Section 7.2(a ). 'TRANSFER TAXES• ' m ans ijll sales. use , value addod e)(clse, registration , documentary, stamps tran fer, real property transfe reoording, gains , stock tra ns f r nd o her similar Taxe � and fees. (b) For purpose s of his Agreement excep a o en'ltSe expressly pro 1ded herein or unless e context ottlerw i se requires : ( i ) words usir>g th singular or plural number also · nclude the plural or singular nurtlber, respe • ely, and t he usa or any gender herein shall be deemett to incfud lh$ other genders ; ( i i) referenc s ere ' n to "Articles,· ' ' Sections ,' "subsections" and olher subdivisions wi hout ref nee to a document are to ti peel ' ed A · ctes, Sections, subsections and other subdivisions o this Agroomtit"lt � (iii) a reference to a subsection wet out further referenee to a Soctloo i s a referenoe to such subsoctlon a contained in the same SeC1ion In which he reference appears, and th i s rule shall also apply to othor subdl · s1ons w · hin a Section or subsection: ( iv) th vtord& ''herei , ' "hereof," "hcrouncter," hereby" and o herv10<ds of similar import refar o this Agreement as a whole and not to any particular pro.,,1slon ; and (v) Che Vi s " lnc r ude ," "il'lclu es" and ' 'including" are deemed to be allowed by the phtaee ' ' without rmitation ." Al l accovntit terms used herein and not Xf::fl3 ly defined herein shall have he m an ng given to them under GAAP . My Rx W all e t P - r a na P rivate L im it e d A sub � diary of M yRxWallet North America Co rp oration UnI d statos of Am e rica

ARTICLE II OEFINITIVE SHARE PURCHASE AGREEMENT Section 2.1 - Execu ·on of Agreoment This D fin bVe Share Purchase Agreement (this ''Agreement"), dat d as of Ju 17, 2025, Js entered into by and be !/een MyRxWallet Prana Private Limited (the "Acquirer"), a company proposed to be incorporated under the Companies Aclof 2013 , as amended, India, and No � h Therapeutics Private Limited (the "Seller''), a company organi4 d under the la of India . WHEREAS the considera · on for ttle acquisition shall be payabl& solely in the form of equity, speclflcally through the i ssuance of 843,750 common stock of MyRxWallet Prana , Private Limited, valued at INR 2,064 (USD 24) per share 1 which shaJI oonsti te the agreed and fixed va l uation or the purposes of this equity � sed transaction . Section 2.2 - Purchase a d Sale of Shares Subject to the terms and wnditions sot forth In th f s Agreement t e Sofler hereby agrees to sell , a � slgn. transfer, .:Jnd convey to the Acq irer , an ·he Acqu i r r agre � s to pure ase from the Seller, seventy percent {70'¾) of the lola l issued a, d o tstandmg equity shares of Noah Therapeutics Private Limited (the Shares ), represeotrng a oontrolllng eq ity i tere t and majority shareholde In the Company . S c on 2.3 - Purchase Price and Share lssuanc The aggregate purchase price for e Shares shall be satisfied enti re ly throug the Issuance of 843,750 common stock of the Aoqulter (the "Consideration Shares"} , each valued at INR 2,064 (USO $24) por oornmon share. The Consideration Shares shall be uly authorized, validly issued , fully paid, and non - assessable, and shall be issued in accordance with the appricable provisions of Indian securities and corporate law , including the Comp nies Act , 2013 , India, and a l l relevant rules and regulations thereunder. These shares shalf be issue<J i n accordance with applicable I n dian • aws and regulat i ons , including: • Section 42 of l e Companies Act, 2013 (Priva e Placement), • Section 62(1}(c) (Preferential A.llofmont}, • Fil ng requirements under Fonns PAS - 4 and PAS - 6 , and • Any other appf;cable statutory compliance requirements . The Parties acknowledge and agree that the implied agg regate val e of the oonsjderatiori is INR 174 .1 5 Crores ( 174, 15,00,000 - Rupees One Hundred Seventy - Four Crores, Fifteen Lakh s Only), equfvalent to USO $20,250,000. which shall MyRx.Wallet Prana Private Limited A sub idiary of MyRxWallet North Am tica Corporation Unit&d st,t s of America

oonstitute the agre d fixed value for the purposes of this equity - based transaction al a per - share value of INR 2 064 (USO $24). The Parties further acknowledge and oonfirm tha : • Th i s valuation has been mutually agreed upon solely tor the purposes of th · s transaction ; • It is not based on any formal third - party valuatlon. appraisal, or independent financial assessment of the Company's condition, marke value, or any other economic factors; and • For the avofdance of doubt. the agreed valuation shall be treated as final and binding and shaU no be adjusted or renegotiated basao on fluctuations in currency exchange rates be en the Ind Ian Rupee and the U . S . DoJlar at or after the date of this Agreement. Furthermore , the Parties affirm at they have each independently evatuated the transac · on and are not relying on any representations or warranties regarding the vaJue of the shares beyo d the mutual agreement as axpr ssty set forth herein: (a) Acquisition Consideration The total acquisition considera · on shaU consist of 843,750 common stock of MyRxWalfe Prana, Private Limited, having an ag eed I lernal valua ion of INR 174. Crores {t 174,15,00,000 - Rupees One Hundred Seventy - Four C res . Fifte Lakhs Only) (USO $20,250,000). se shares shall be allocated as follows : • Listing Day Ves · ng : The Seller shall receive 125,200 oomrnon stock {mternally valued at I R 25 Crores and 80 Lakhs / USO $3,000.000}, which shall vest immediately upo1 tJ1e ffecti e c 1mencement o trading of MyRxWallet North America Corporation's commons ock on a natJonaJ securities exchange or quotation system pursuant to a Dire Public Usting ( DPL'') (the 0 Llsting Date") . These shares shall become el i gible for trading publicly upon such listing, subject to applicable securities regulations and any fi quired compliance or transfer restrictions . • Milestone - Based Vesting: The Sefler·s rema i n i ng 125,200 common stock (also fnternally valued at INR 25 Crores 80 Lakhs / USD $3,000,000) shafl vest In four (4 quaf installments of twenty - five peroent (25o/c) e ery six (6) mon s over a period of tvventy - four {24) months following the Listing Oa . Theses a es s alt b subj ct to the Securfties and Excha ge ommission's appl i cable lock - up restrlc ions and shall be held i escrow by tf'le Acquirers legal oou sel or another rnut alfy agreed - upon designated escrow agent. The shares shall b � reJeased to e S lier in accordance w th the agr ed ves ng schedule, and dis ursed at eac distributlot1 interval, subject to customary administrative and d i sburseme t fees. (b) Strategic Equity Growth Alloc - atlon • A total of 500,000 com mo11 stock of the Acquirer, havl g an i erna I valuation of approximat ly INR 103 Cro 20 Lakhs (t103,20 . 00 ,0 00 - R pees One MyRxWallet Prana Private Limited A sub lcflary of MyRxWaUet North America Corporation Unttc<I States of America

Hundred Torno Croros, and T � enty Lakhs Only) (USD S12,00O,0O0). shall be designated as "Strategic E � uity Growth Allocation", These shares shall be reinvested into the Seller and its operations, under the direction and strategic oversight of e Acq lrer's parent, MyRxWaltet North Amenca Corporation . • The Strategic Equity Growth Allocation shall be utilized to s pport Noah Therapeutics' worldng capitaJ needs , operational expenditures, and strategic growth Initiatives, including but not limited to mergers and a oq ui itions . U S marke entry, and modernizatio of manufacturing and research facil ties . al l 1 accordance with he Acqu rer's board - approved flnanelal and development roadmap. • These shares shaU be issued immediately upon exeet1tio11 of this Definitive Shari Purchase Agreement (SPA} and shall remain restricted secur • i s wit in the meaning or applicable Indian securit i es laws . The issuance, holding. and transfer of these shares shall be subject to compliance � ith the Companies Act . 2013 inclu ing but not l t mlted to Section 42 (Private P f acement ) a n d S ction 62(1){c} (Preferentiat Allotment) , as well as the applicable rules framed t • ereunder, including the Companies (Prospectus and Allotment of Securities) Rules, 2014 : • In add i tion, the shares shall be governed by all applicable provis · on � of the Securities and Exchange Board of lndia ( � EBI} regulations, as amended, a d, where apprlcable , e Fore g Exchange Manageme t Act . 1999 (FEMA) and relevant ot · i ca ti ons issued by the Reserve Ba k of India (RBI), • No transfer or disposition of these s ares shal I be pe m li tted unless al I regulatory approvals and co d tions nder Indian law, including filings with the R gistrar of Companies and applicable RBI permissions (i required ), have been satisfled . • The shares may bear a restrictive legend ind i cating sue Ii ilat i ons, an d the Seller ag ees to comply with all legaJ requirements under Indian s curities and corporate law prior to a y proposed transfer . (c) Employee Equity Retention Plan As part of the u - ansaction. a total equity pool not to exceed INR 4.30 Crores { pproximately US $500,000}, representing up to 20,833 commons ock of the Acqu i rer . shall be reserved for allocation to elig i ble employees of r eoord of the Seller as of tt1e Clos i ng Date, These shares shall beg anted u der the Acquirers Employee Equity Retention Ptan and will be subjoct to the following terms : 1 . The shares shall be distributod among all qualifying employees of record, unless otherwise deteonined by the Acqufrer's Board of Di rec tors in accordance wi app l icable � mployment levels. responsibilities, o r tenure - bas , ed criteria. MyRxWallet Prana Private Limited A subsidiary of � yRxWsllet North America Corporation United States of America

2. The allocation will foJlow a vesting schedule tied to continued employment , with vesting occurring i n the following milestones: Iii. i . End of Year 1 : 5 , 208 common stock, equivalent to INR 1 , 07 , - 50 , 000 (lncfan Rupees One Crore, Seven Lakhs and Fifty Thousand only or US $ 125 , 000 , based on a price of INR 2 , 064 per oommon stock . II . End of Year 3 : 7 , 812 common stock, equ i valent to INR 1 , 61,25,000 (I dian R pees One Crore, Sixty - One akhs and Twenty - Five thousand only) or USO $187,500, based on a prjce of INR 2,064 per common stock. End of Year 5 : 7,812 co mon sock, equ ival ent to INR 1 , 6 ,25 1 000 (Indian Rupees - One Crore, Sixty - One Lakhs and T • - 1enty - Five Thousand only) or USD S187,500 . based on a price of INR 2,064 per common stoc . 3. AJI equity awards shall be governed by th terms and conditions of the Aoquirer's Employee Equity Retention Plan and, to the extent appticabJe, in accordance with Ind ia n regulatory standards, including those set forth under e SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 . 4. lnd ivld uaJ award agreements, vesUng te r ms, exercise cond, tio s (If appticab l e) . and any imp l ications shalf be communicated to eactl eligibre employee fo l lowing the Closing Date, and shall be executed in accordance with the Acquirer's standard equity award practices. (d) Assumption of Liabilities The Buyer assumes all curr nt liabllftles net of cas receivables and incl d i ng I nventories o tstandl og as of t h e record date, tot a ling approx! nate ty INR 15,05,00 ,000 (R pees Fifteen Crores and Five Lakhs Only) (US $1 , 750,000) eq ivalent to 72,916 common stock , (e) Seller's Vesting Schedule and Perfonnance - Based MIiestones Each mi !&stone shal I serve as a condition precedent the vesting of th e corresponding share tranche. The vesting shalf proceed in four ( 4) equaI installments of 31,250 common tock very six (6) month , subj ct to h ac i v nt of m tually agreod milestones : • MIiestone 1 (Months 0 - 6) - I nltlal Integratlo n and Strategle P l anning : Within th first six (6) mo lhs following the Closing Dat e, tha Sell r shall support the MyRxWallet Prana Private Limited A subsiQiary of MyRxWatlet North Americ= - Corpo1'8tion U lftcd Stat of Amcrk

lntegra on of 0 \ e acqu i red assets Into Acquirers ecosystem , i ncluding cultural and governance alignment, strategic planni g for mergers and acqu 1 s · i ans, revenue enhancement initiatives, employee stock ownership plans (ESOPs) , and foundational preparations for ure capital rals � or spin - offs. Upon satisfactory completion of Mi lgstone 1 , as determined by the Aoquirer i n good faith, 31,250 common stock shalt vest at the end of Month 6. • MIiestone 2 (Months 7 - 12} - Exeoution of Growth Strategies : During his phase, the Seller shall assist 1ith execu ·ng the s rateglc g r owth pfan, 1 nduding trac ng measurable outcomes of 1he acquisition, ovaluating cul raJ and techoofogy i tegration, achieving revenue growth targets of at l east 2x to10x , and [nitla · ng capital raising efforts. Upon comp le lion of Mlleslone 2, a the end of ri., onth 12 . co mon stock 31 , 250 shall vest. • Milestone 3 (Months 13 - 18 ) - Spinoff Preparation and Consol dated Impact RevJew : This milestone involves a consolidated review of Miloston s 1 and 2 , confirmation of their succossful completion, and the preparation for a strategic splnoff of the Seller, subsi iary . Upon oompletlon of Milestone 3 , at the end of Month 18, an additional 31,250 common stock shalI vest. • Final Milestone 4 (Months 19 - 24) - Seller IPO Preparation : Upon the satisfactory completion o all prior milestones. and active p eparation for an initial public offering {IPOJ in cittior t a Uni ed States of Ame · ca, In d ia, or bo 1 Jurisdictions, the remaining balance of vested shar s . 31,250 commons ock s all be rel asoo in full to the Seller . The Seller acknowledges that vesting Is s ctly performance - based and contingent upon the Acquirer's reasonable determ i nation that tne above milestones have been me i. Closing Term : The closing of the transaction (the Clos i ng") shall take place on or before June 20, 2025, or on such oth - er da e and time as may be mutually agreed upon by the Part i es l n writing . The Closing shall be deemed effective upon the completion of al I conditions pracodont and the mu al exchange of required deliverables. i ncluding e transfer of the Shares and issuance of the Co siderati Shares . Issuance, Vesting and SoctJrlt' s Con,plianc;e • Upon ex.ecut i on of this Agreement , the Acquire stiall pro o y in s t cl i t s duly a · po nled stock Transfer / \ geri of record o nitlat lt e issuat1c of the <;1pp ' ica I equ - y co :sideration to the $ha aholders designatec in writi g bi the Seller . MyRxWallet Prana Private Limited A cubgidiary of MyRxWallet North America CofJ)oratlon United States o Amcr'lea

• Eq ity sharBS that ar& mtr \ ed i ately v sled in accordance • h the terms of his Agreement shall be issued and delivered wi hout delay, subjoct to applicable restrictions under federal and state securities laws. • Equity shares subJoct to a vos · ng schedule or escro•N oonditions sha1I be issued in book - en.try form ahd held by the rans er Agent or an ap ointed escrow agent, to be released in accordilnce with the agreed vesting mllestones and any appl able !llseto � , agreemen . 2 . 5 Assump · on of Liabirtles : The Acquirer shall assume, and shaJI not be deemed ,o a ume, any llabl ltl so, obligations o the Sel er e � ceeding the specified amount herein INR 15,05 , 00,000 (Indian Rupees Fifteen Crores and Five Lakhs only) (US $ 1 , 750 ,000) urval nt to 12,916 co mon stock, wfle her no vn or known . disclosed or undlsclos, d . conti11ge11 or otherv ise, including but not J I I ed to any Ta.x Lisbilities, deb{s, cla i ms , lawsui s , or contractual obll aHons axi Ing prior or of the Closing Date. Any liabi rties no spe<:i • ed h ... rcin and oxcoo - d ttie ar c>unt s ' II amain the so l � <1nd xcl JS ve , spo slblllty of the S lier. 2 , 6 Excluded Assets: Th i s provision applies only to asse � o vned by tie oc,n,pa y . Pen;onal assets of the Sellers or af"ly rnem o' th Board of Ƒ · rectors, ;ncluding tho e pledged as oollaleral wiUl e ls rng lenders or banking lnstiru ·ans, a e expressly excludocJ from mis transaction . Such personal assets shaJI rnmain s so{ proper - ty ;Jnd re � PQn ibitity o their re pectlve ners. 2.7 Exe ded Liabilities: The,e ar&no Exclucled U � bir ·es. 2.8 Legal Fees : Each party shall be sol ly tespoh i e tor lhe payment of i own lega l fees and expenses inet1rrea in connection with the negotiation, pr para lion, x utlon, n performanoo of Is Agr ment, irclud i ng the hiring arid engagement o legat counsel. ARTICLE Ill THE CLOSING DATE ANO TERMS 1. Closing : The clo Ing of lhe trQ &actions OCJl empla ec hereby (the • Cl OSI NG·) shalJ ta u place conte poraneous with 1he exec Ion of this Agree r nent ur I ur µ1101 tu J r 10 20 2025 (the ·cL.OSING DATE"), 2. DeUvery of Items by the Seifer: ne Seller sllell derwer to the Acquirer at t e Clos i ng the items listed below: (a) All documentation neoessary to ffectuat& he tr � n fer o Seventy peroent {70%) of 1he Issued and oulstandi119 equily interests of SELLER. to the Acqulror, thmugh Its de lgnated stock transfer ag t of rooord. shaJI be pMpared, exec:uted, and delivered within 7 - - 0ay post • closlng . OR The Soller sh al I engage a licensed Stock Transfer Agent or Charterad Acoountaot to · ssue a affidavit oerttfying that they represent the S Uar, and that based on the structure of the transac ·011, t e s are transfer shall be exeouted and deliver upon SEC confirmation of e buyers' S - 1 "Effective" and shares have is declaro MyRxWallet Prana Private Limited A subsldlaty ot MyRXWallet North America Corporatron United States of America

unrestricted shares. Th affidavit shall be provided to lhe Acq irer's legal co nsoJ p rio to the Closing Date. (b) Cooculi ently , the Sellers representa · ve (CPA ) shall furnish documentatiofl recogniz.i Acquirer, as the official majority sharetiolder of reoc,)ld , entitled to fuU governance gl11s at1d owoors f , - p of - Seventy perc.:enl (70%) of Seller. effective upon e execution of the De itive Shar Pu rch ase Agreement . (c) Any required cof'J)orate resolutions, board consent , or share registers reflec · ng the transfer ; (d) Any other agreements or I nstruments reasonably requested by the Aoquirer to effectuate the terms of thIs Agreement (e) 81 \ Y other documen nd mstruments as 1he Acquirer m,Hy 1'1.:1 onably req e t The Acq Ir - will issue the ag. - eed - upon 843.750 common stock to the Sel r and separately to the company upon th eJ<ecu n of th i s SPA, through Its SEC reg i stered Stock Transfer Agen . The issuance of these shares constJtutes de facto cor,fi rm lion of the equity trem • cclon and satisfies all conditions roqulred for Closing . Accordlngly . all item ·nall bo delivere<:l d i reollv to the Acqu i rer without escrow. 3.3 Delivery of Items by Acquirer: The Acqui e shall deliver to the Seller, with n scventy•two (72) hours totlo l'l9 the Closing, the folk> \ ng Items: (a) Share Certificatas or Book - Entry Con atlons l.ss ed by the Stock Tra srer Age of r � oord , evidencing the issuance or the Acquirer's common stock representing the equity ownership ; terest i n Acqulrer, as set for1h in th s A911 0 ent ; and {b) Certificates or O cial Receipts oot1f 1 rml g tho book entry registralion of such shares in ttie name(s) of the Sellar or d s · nated rec i pients, dooum � m :j ng ownership of thP. appl.c:abl Acquirer shares r n ccord noe with the terms of is Agreerr1 e1 . ARTICLE I V REPRESEN T ATIONS ANO WARRANT I ES OF THE SELLER As an induoernent to the Acqulr<ar to e er into t is Agreeme 1, Saller presents and wa r the Acquire< as tollows : 4 , 1 Au ori tion: he Sel1er r epresents ard � rrants that i has conducte indepe ent due d i ligence , fully uooerstands the terms of this Agreer nt, and Is entering into this ansact n voluntarily and , · th lnrorm d consent. The Seller acknowledge a d agr that upon xecutlon of th · s Agreement, Selle r, shall become a subsidiary of Acqu i rer . The Seller further represents tha t as full power and atJthorily lo execute nd deilve, this Agreem n 1d an � related Ancillary Agreements, nd to perform Its obligations hereunder ancl thereunder . Th is Agr me nd u,e An ci llary Agreements , ave oee11 dJly ex.ecu1 d and MyRxWa ll et Prana Pr i vate L i mited A subsi � iary of MyRxWellet North America Cotpor tlon Un lted $1stes of America

dal ered by the Seller and. ossumlng the due authorization . execution . a delive - ry by the Aoq irer, constitute valld and legally bind i ng obugatiorlS of the S I enforceable in acoordance with the ' r re pective tem,s . 2. B kers and Legal Fees : ach P � rty shall be sole[y spor slble lor a11y and al l legal advisory , brokerage , ir,der, acoounting, con lJlt i � fees i t incurs in conn c on v 1 l 1he nogouanM. execution, and consumma on of the transactio 0011 emplated y th Agreement, unless otherwise expressly agreed to In writing by the Parties . No agen, broker, nder . inv strn nt ban er. flnancial advisor. or other simi la r ntermediary shall be entitled to a y fee, commission, or othe compensation In connection with this transaction based on a y ammgemerit made by or o behal of the other Party 0< any of Its AffilJates . 3. Non � Contravention : Neither the exeCtJtion , delivery or perfomiance of this Agreement ct he Anci lary Agreements. as applicable, n r the collSummation of th transactions oon emplated hereby or thsreb,y · 11, vith or vithou the glvlng of no ce or the lapse of time or both, (I) vlolal any Law or Order or other restncllon of c1ny Go,• mental Entity to ,c the Seller may be subject or (ii) con 1(;1 wi , resul in a breach of. constltu1e default nder, esult in tho ace I ration of any right or obligation under, cteate Ir Any party the • ht to ace I ratti. terminate , modify . cancel. require a y n orc e v der or esult in the crQa .)(I <Jf fr P.n on any of the Assets under. � :,ny Contract to which he Seller is a party or by w c:h i is bound and to , ich any of ts els is subject. 4. Lltlgatio : There is no pending or, to the Knov ledge of the Soll r , lhraa ened Aaion against o afft1cUn9 the Assets . Neither the Selier nor tJ,e Ass&ts ar ubjecl to any Order restraining enj ' ni g er other,vise prohib . ing or ma Ing lllagaJ any action by the Seller. this Ag � em nt or any of the transactions oontam atecl hereby . 5. Co tracts : Except as set forth In Schedo le 4 . 5. there are no excCtJtory con1tact , commitments, agreements, or arrangements (whether writ - tell or oral, including but oot limited to l � ense agreements. devo &nt ag ments, joint ventures, distrlbu on a,ra ments, or strategic partnerships) to wh i ch any of ttle Assets are bound or 1ect, other than this A reernent. Tho Soller further represents and warrants that If t am exist � ny prior , e1e;isting . or a tlclpat � d contra u I agreements - \ ether wrl n , oral, f orma l . or i fo al ha {a) relate to the Assets oc operations o oah crapeutlcs , and ( b} ti ave or may reasooa be expected 1o hFJve a ma erial lmpaot - financlal, operational, or legal n oah Ti erapeutics o r its business aft t e Clos trg. such � reemenls mtJst be disclosod In f ull and del i vere<:tlo the Acquirer as part of Schedule 4 . 5 prior to Closing. Fa lure lo di sc lose any su ag ement shall constitute 8 materia l breach of ttf s Agrooment and m y result in appropria c rom ies . n c luding indemnification and potontlal ta mination rig ts , as proviood ls 9 Whe,e in th · s Agreement . 4. Intellectual Property : Se ler represents and warrants t at : MyRxWallet Prana Pr va e Limited A subs:ldlilfY of MyR.xWall � t North America Corporation United St tos of America

(a) Schedule 4.6 conti:!ln.s a list of all pcrtents, trade "ames, trademarks and/or oopyrighls and all applic lions therefor owned by Seirer with respect to th Ass ts and alt lioenses if any relating to the foregoing patents trade names � traderr rks a /or copyrights an aII applicat ons therefor . ScheduJa 4.6 Ida llries the owner of each i tem listed thereon and , Int.no cas � of re,gisfrations and appl1calions, the application or registration number and data . ha Seller has not taken any action that could rosutt in arw of tl1e r&glslratlo s ar'ld applictllions or registration for the Asoots not heir � valid and In full fOr'CA and effect. {b) Except as d i sclosed on Sch dule 4 . 6, the Sell r is t o sole and exclus i ve o � 81' of , and has good nd m fk ta l e tiUe o, en the In ellectual Properly in and to he Assets , inciud i ng the Intellectual Property set forth on Sciledule 4 . 6, free a11d clear of all ens. Except as lsclose on Schedule 4 .6. the Sel f e, has sole and ex.elusive ri ht to dev � lop, perform, use, create derivative works of, operate, reproduce, market self, license, display, distribufe . publish and ttan mit tho lnt oJ lcctual Property In and lo the Assets . Upon the Closing, excopt as isclose on Sche le 4 . 6, the Acqu 1 rer � i l l have sole and exclu ive ri9 t, Litle and lt1lerest In and to lhe lntcllectua l Property · n and o the Asse , such tt \ et the Aoquirer sha11 lhereaftar ave sole ar c,l xciuslvQ rlgh to perform, re produce . create derivative wor1ts of , develop use. operate, market, sell, rcense, d splay, publl h, transm ta d distr i bute the Assets, free of all enc mb ances . The Seller has taken reasonable measures o prote<.l l � propr'le ary nature of the Intellectual Property in and to the Assets and to ainta i n in confidef'!ce ttte trade secrets a � d confidential in formation hat i owns or u - ses . Exoe as d i sclos on Schedule 4 .6. no other Persoo has any rights to any of I tellectual Property ir and o the Assets an , to the ledg of the Seller, no other Parso Is lofrlnglng, l olating or misappropriating any of the Jntellectuaf Property irs and to the Assets. {c - ) Wi h respeci to the Sal els lnlellat;1ual Prnp&rty cort buted to e Assets . such Intellectual Property does not infringe upc>n, violete or ootistitute.a misappropriation of any Intellectual Prope y or other right of any o·her Person . tn addition , to SelJer' knowledge, nooa or th � lvlti or business prese Uy conducted by ths Sell r with respect to the Assets infringes or violates , or constitutes a misapprcp ' ation of , any lntelrectual Ptoperty or olh r right of any o r Parson. Neithe r the Seller nor any Affiliate of the Seller has received any written complai11t c � im or no � ce alleg i any such nHngern nt, vlola on or misappropriation . Further. neither t e Seller nor any Affiliate of the Seller has d . closed to any Person, any produ orm la or des · gn, or any portion or aspect of any product formula or design . wnich is part o e Assets, incfu - ding Intellectual Property . 7. Tille to Assets: Except as to Intellectual Property (, ich wa r ranty is co taineo in Section 4.6) : (i) the Selle has good and marKe b f e title Lo all o f t he Assets fre - e a11d clear of al I Lien � · (" i) th · s Agreement aoo the i ns uments of transfer to � e executed and der ere - d JJU s ant hereto wlll effectlvely vest I e Acqulrer goo a d 1arketab1 e ti � to a l l of the Assats free anc clear' of all Lfe11s; {in) end no Person other tha,i he Sel r has any ownership in erest in any o he Assets . 8. Investment Representations: Seller and those ,eceivir,g shc:1 a in A - cquket r ptesent and varran lhal: (a) Se J ler a d hose receiving the shares are aware of the Acquirer's business affairs ano financial condition a d has acqu i red su cient information abou Acquirer to reach an nformed and knowledgeable decision to acquire \ he hares that t:onstitute the Pur'chase Ptioe. Seller and MyRxWallet Prana Private Limited A subsidiary of MyRxWatlet North America Corp«atlon Unlted States of Amcrlc �

ttlose receiving the shares a1so ackrloWledge lhat lhey are relying sol ly on their own counsel for legal advice, and no on any statements Cl( representa1iollS of Aoquirer or its legal counsel or agents ror legal advice v · th re p t lo tlll nv � tment o the transactions oont&mplated by is Agreement. (b) Seller and those re - ceivi119 shares are acquiring the shares or I vestm t for their own account ori and not vith c1 view to , or Or' resale r n con, oclion with . any "d1str but1onr tnercof W l ltiln the meaning of the 1933 Act or u der any appficable provision o state l aw . Seller a d those receivirtg the sbares do not havG any pr s nt I tentlon to transfer 1he shares to any pe,son or enti y . Seller and those reoeivir,g the share re awere that their lnv � slmt1nt ul Acqu1rt1( I � spaculativ Investment that has limited liq idity and i s subject to the risk or oompJete loss Se ler and those receiving the share are able. v.tithout impairing their financic1I condition. to hol the shar - es for an indefinite period and to suffer a complete Joss of Its rnvestment in the shares. (c) Seller and those receiving shares understand ttia the shares that oomprise Cha Purcltasa Prioe have r'lot been 1"4:!gi!i et d und tho 1933 Act by reason o a specific exemption therefrom , vhich exem pti on dep8llds upon, among olh r lhlngs. Cha bon � fide naturo of Seller's Investment It t nt as €lXl)(CSSOO herein. (d) he Seller afld any individual or entity receiving shares p � rsuanl to this Agreement scknawladge and agr � ti ,at the shares belng issu d are � stricted secu iti - es under a icable I ndrat1 se<:umies laws, including tl',e Corn , ani s Acl, 2013. he Co panlss (P ospoct s and Allotment of Securities) Rules, 2014. and where applicable , the SEBI (lss1.Je of Cap"4:!I an"d o · sclosute Raqu l rements) R99ulatlons. as amen d. Pu rs anl to thi!!se laws end rules, recipients may be roq ired to ho the s ares for a s ecified pefiod and may not transfer, sen, or o he � • e dispoaa o such share � ut1lass sucl1 transf8r cornpllos wltti aH applfcabae Indian corporate, seoorities, and exchange control law , • � ludlng spprovals or � xemptlons und r the Foreign Ex.change � . an:agomcnt Act. 1999 (FEM ) and,'or RB I guidelines, where applicable . Tot e exteflt Ulat U . S . securities iaW$ become relevant ( . g . , In th context of a subsequent listing in the U.S. or an offertng under Rure 144 or Regula lion S) , the Seller and recipients understand t1'1at the sha, s may also bs treated as "restricted securities" under tt,e U . S . Securities A.cl of 1933 . and may not be resold or transferred i r'l tile Un i ted State - s absent registration or an a ia i lable exemption . The Acqui rer s all have no ob igation to r'e{} I 181' th � shares wilh the U . S . Secvrities and Exchange Commlssron {SEC) o r qualify them under sate securities laws, and any exemption hat may apply could be subject 1o oondrlions beyo id he cor rol of tba Selle, or fi cipien s. ARTICLEV REPRESENT ATJONS AND WARAANTl£S OF THE ACQUIRER As an inducement to th Seller to ant r Into Is A9roemc t, t e Acqui er epresents aino warrants to the Seirer as follows : 5.1 Authorization: The A � 4ul r er has full o er and authority to execute and der er thi Agreement a d the Ancillary Agreements, as app • able, and to perform Its llgatlons h reunder and e,eundor. This Agl'{lamcmt and the Ancillary Agreements have been duly MyRxWallet Prana Private Limited A t.ubsldlary of M � RxWallot North Amor �� Corpor � tlon United States of America

e>eecuted and de livered by lhe Aoqu i rer an - d, assuming the due � lJthorlzalion, ex&eutlon and del very hereof and ttloreof by the Seller. constirute 1he valid and legally binding oblig,at»ons of the Acquirer enforceable in aocor<lanoe wrth el resl)(lctlve terms. Acqu rer is a P r iva e Limited Company organized urnier the laws of the State of Te an - gana, India, In good stand n � . and has obt lMd all onsents and otl er approvals necessary underTefangaria ta :Y, it'S Articles of Incorporation, alld it$ Bylaws neoessary for cuti . der ery and perfo an.ce of tnis Ag1eement and the Ancillary Agreement$ . 2. on - Contravent i o : (a) ellh r ihe execution. deli'lery or performance ot Uiis Agre,emen or tt a Ancillary Agreemerits, as applicable, oor ":1 0011summation of the transactions oontemptate<:I hereby Qr lhe,eby will, with or without the giVing of no iv � or tt l � p e of tlm or oth. vrola ea y Law or Order or oH r Uictlo.n of any Governmet1tal Entity to wtlich the Acqui t er may b& subjecl {b) The oxocution and delivery of tnjs Agreement and the Atlclllary Agreements . as applicable , by the Aoqu ir&r does no and the pertomiance oft is Ag � emel \ t and a Ancillary Agmsmoots by the Acquirer and tne oo.n6u.mmatlon of th � transactions oontempfated herel>y aoo thereby II not , r u ire any conscn approval, aulhon:tatioll or perm t of, or fll i AQ with or notification to . any GovernmentQ Entity. 3. Brokers and Legal Fees: Each Party shall be solely respon!.iblA for any and all legal. advi � y, brokerage . fuldec, acoountir,g, or oohaul1Jn � f s • t lncu,s • n connec ion witti he negotiation, execution, and summation of lhe transactio s oontem IJlted by th is Agreoment. unless othsrwise expressly agree<! to in wt'i i g by Pa · � s . Tne Acq irer has a Master Agl'eemont wlth the - agent/finder for th is - · pe<;ific tran action.. The agerlV nder shall be compensated pursuar,t t Mas or Ag eement. o a<.;1ent, broker. finder , investment ban er, financial advisor . or other s · milar intermediary shall be entitled to any fee, commission, Of ot er compensation in connection with this 1ransac · on Stid on any arrangem.., t made by or on be alt of e other Party or any of it Afftllates. A,RTICLE:VJ CONDITIONS TO OBLIGATION TO CLOSE 1. Conditions to Closing by e Acqui rer : The obliga · on of the Aoquirer to effect tho transactions contern plate here y Is subject to the satisractio:n ot waive r by the Acqu i rer of Ule followi conditions: (a) The representations and warranties of certain of the Seller set fo rth In this Agreement shall be lrue , md o0tr t In all material respects . · wit re p c t to ropresentations a d warrant s r'lot q uactfled by aterial � ty , or in aH respects, vith re spect to rep r esenta ion$ and � am:inties qualified by ma erlal ty as of th daka oft is Agreernen and as of the Closing Date as 1hougt maoo on and as of the cosing oa ce. (b) The Seller shall t,ave JM3rformed in aa mate r ial e pact the covenants require<l 1o ba performed by .it under this Agreemen at or p,lor to the Closing Date . MyRxWallet Prana Private Limited A subsidiary of MyRxWallet North Amenea Corporation United States of Amorlca

(c} Th S lier shall have exocutcd and dcflverod each of the Anclllary Agl"QQmonts, as applicable . {d) There shall be no effective or pending Law or Order - that would profl ' bit the CIOslng , and the Saller shall h.ave obtained all necessary approvals of any Governmental ntl • in connectlo with the transactions contemplated hereby and by the Ancillary Agreements . (8) Tne Seller shall have delivered each of 1he i erns described In S � clion 3.2 . (f) Seller shalr have conducted its bu ir1ess only IJ1 th ordinary course and shall no1 have acquired or a mod o acquire as pa of the busm s all or any substantial ponioo of :he assots or business of any other business organization by merger o oo solidatioo, ·tock purchase or asse purchase without Acqulrer' ppr'oval In writing. (g) Seller shall have com tad Ul.C approval of this Agreeme - n t c:1r1d Anclllary Agreements as r � ulred under its articles of orgamzatlon , opera ·n - g agreements, and th � la vs of the,urf sdlctions where it is sul>Ject. (h} There - . re no appraisal r ights (dissenter's rights) asserted by any owner of Se ler iri connection with tti' s tr � n actlo . 6 . 2 CONDITIONS TO CLOSING BY THE SELLE R The obligation or the Sel � to fl c t the tr nsactiofls contemplate her by I � subject to the satisfaction walv : r by the Se ler o f the follov ir 19 collditions : (a) he representations arid warrantlos o the Acquirer set fo 1111 this Agreeme t shall bo true and correct In all material respects, with respoct to representationi:. ;:md varranties not quallficd by m teria r y and In all respects, witfl respect lo r prnsontations and var anlies qualified by ma erlallty, in ach case a of 1e dat of i s Agreer - nen and Hs of Clos,rg Date as oagh ma e on and as of the Closing 0a1 . (b) The Aoqu , rer sha l l ha e performed in all mat r al respects the covenant r'eqo 1 rod to be p rformed by it under i.s r mofl a or prior to the Clos i ng Oat . (c} The Aequl'8r sr.all have execu ed and d lvare<l each of the Ancillary Agreements , as appl etble. (d) Ther - e shall ba no affi : t!Ctlv or pending Law or Order tl \ at would prohi • the Closi 119 , Bnd the Acqulrer � 1 all have obtained all neoesse . ry app ovals of any Govemrnenlal EntltiBS in connection wit the nsactions co tamplated hereby and by th Anclllary Agreements . {a) The Acquirer shall ave dolive cd each of the item9 e a - lb8d · n Soction 3 . 3 . ARTICLE VU POST .CLOSING COVENANTS MyRxWallet Prana Private Limited A stibsldlary of My � :icW$lte - t North America Corporation Unltod Sta - tos. of America

1. Transfer Taxes; Not \ • hstnnding anything herein to the oontrary, Aoquirer shall be liable for and shall pay imy Transfer Taxes or other similar tax i mposed in connecoon with the transfer of the Assets pursuan to his Agreement. The party re..pon bis under applica b e Law for remitting any such tax shal pay and remit such tax on a timely basi and, If such party Is tho Sollor, tho Seller hall notify tho Acqulrer of the amount of such ta;c, and the Acquirer shaJI pl'OmpUy pay to tne SelffW the amount of u e h tax. 2. Further Action : From and after the Closing, each party hereto shaJI execute and deliver any documents and take au rurthef a • ns as may reasonably be required to implement the provisions of this Agreement and the Ancillary Agreer e ts . and to g i ve e ·ect to ttie transac f ons cont mplatcd herein and therein . is inclu - de • e surin that the Acqulrer obtains effective ow11ership an control of th Assets. ARTICLE VIII M ISC€1.LAN EOUS 1. Survival : Notwithstaf')ding any right ofthe Acqu · rer (whether or notei<ercis.ed) to ln ... esttgate the affairs of U � e Seller or any right of any party (whe er or not exar soo) o inVl}Stigale the accuracy of he repte a latJoos and varr.:intles of 1he other party c � m ained in tl \ l s Agre - ement or lh waiver of any ooodition to Closinig, each uf the parties hereto has tile right to re y fully upon the !"$pres t � tions. warTanties, CO';'enants afld agreemenls of the olher contained in lhis Ag r eement . The re 5entalions. warranties . covenants and agreements of e partl s hereto c ntaincd in this Agreernen and any oef1ific$l8 or other document provided heramder Of there nder \ II I survwe the Closing. 2. No lh ird party Ben eflciaries ; The terms ahd provisions of this Agreement are i tended solely for the benefit o f t r ua Patties hereto and cir respective successors and permit ad e s i gns, and It I s not t intention o the Parties to c onre thIrd - party ben fie ary r g ht , and his Agreemen does no conf8t any such • hts , upon any o � er Person , 3. Entire Agreement Thi Agre - em � , (Includ i ng thQ Exh . bits and the Schedu es here o � consti te the an N:J ag r eement between the Parties he et o · th a eel t o th � ub J CCt ane · hereof and thereof and upersooa any p lor understandings . agreemen ts o reprasentallmls by or etwecn the Parties hereto, •r.it en or oral , with respact to such subject matter . 4. Succession and Assignment: This Agreement shall be binding upon and I n re to the b nefit of tho Parties named herei and heir res � tiva successors and permitted ass · gns . No Party heret o mity ass,gn either th i s Agreement or any ot i1s riohts, int r $ls or obligations hereunder without the prior written al) roval of tho other Pa • s hereto . 5. Drafting ; The PatlitiS have particlpamd jointly in the negotiation and dro r r \ - g Qf thls Agreement alld, i n the event an ambigui y or question of , tent 0t lntorpreta � on arises, this Agre4ament ha ll be construod as if drafted jointly bt e Parties and no pra s umptlo or burden of proof shall arise favoring or d 11 1 avoring al \ y Party by vi uo of the authorship of any of the � r6vls 'o nt of th s Agr<}cment. 6. Govemlng aw : Th s Agre � ment hiill o e gov e rn 4l d by, and con s trued in ccord a, wi h 1he laws of the Stat of Wyoming an!! in State of Telangana, Hyderab a d , I Nlif:1 . wi t hout g w 1 u y MyRxWallet Prana Private Limited A sub$idiery of MyRxWallet North America Corporation United Ststes of America

effect to any choke o law or conflict of law provlsio11 or rule that would cause lhe applioation of the Laws of any juri sdiction other than the S ate of Wyom • ng and St<1to of Telan9El11o, Hyder � bad , India . 7. Amendments and Waivers ; No amendment of any provlsloo of thii:J Agreemen shall be valld unless such amendment i s in vrltlng and signed by eE1ctl of the Parties hereto. Now - av by any Party hereto o any default. lsr&p esentation or breach of warranty or covenant hereund r. whethQ - f Intentional or not. s all be deemed to extend to any prior or $1Jbsequent def au It, misreprese taoon or breach of varranty or oovel \ 8J'lt hereunder or affect in any way any rights arising by virtue of any prlo or su s � ue11t such oocurrence . No waiver shalr be valid unlaS$ uoh wa · er i in \ lri rng and signed by the Party against whom sud'I waiver · sought to be enforced . 8. Severability : If any pro · sIon o1 his Agreement · s held to be illegal invalid or unM orce.ible unde any present or future Law al \ d if th& rlgh s or obligations of ny Par y he eto un<.Jsr th s Agr'i:!e.. - ,e it · 11not be mate ally ar \ (J adverse1y affected thereby , (a) � ch p ovision will be fu ly severable, (b) th · s Agreement, · 11 be oonstruea and en·orced as if such ii egal inva l id or unenforceabl provlsjon had never cooip isad a part heroof, (c} th r maining provisions of this Agreement · 11remain in f II force and effect and will no be affected by e illegal , inv lld or' unenforceable provision or by its severance here from a11d (d) in lieu of suet, illegal, invalid or unenforceable provia·on, th - ere wi boadded automatically aa a part of is Agreement a legal . valid e11d enforoea le provision · m · Iar in 1 rms o such ill � gal, invar or unen orc � ab e provision as may be possibte . 8.9 Expenses : Except as atherw J a expr sly set forth hereµ, o there n, ch of the Parties holllto w i ll bear its own costs and expenses (inctuding iegai fees and expenses) incUJrcd i n connection with U Is Agreer ar)t tt Y Ancillary A J nte11ts ar)d 1he lr'ar sections oontemplated hereby or 1tiereby , whether the tra sa - ctions oontemplated hereby or thereby are consummated. 10. lncorpor � t1on of Exh i bits and Schedules · he xhi i , Annexe and Sched les identified in ttlis Agreemen are incorporated herein by ref erenee and nado a part h reo . Unloss othcl' \ vlso speciflod, no Informa on oontalnod I an � , nur bera<l Schedule shal I be deemed to b8 contain d In any other num ere<! Sc � . e - ss explicitly in <led 1herein (by cross reference or o hen · se) . 11. Specific Perlormance : he P , a ue he reto agrP.e - 1hat Irr: ar ble damage vould occur i: any provisioo of this Agreement was not pe:f om,ed in accordance · with too t{}r ,s, r f c1nu that t e Parties sholl be entitled to specific performance of the terms her"eol in addition to any oth r remody avallablc to them � t law equity, 12. Head i ngs : The dose • ptivc hoadlngs cont.a ned In u,Is Agreement are il' \ c luded for c;onve lence or reference o ly and sh.all not affect in any way the meaning oc interpretation of this Agreement. 1. :3 Counterpar'.s : This Agreem nt may bo executed In one ƒ ' more oounterparts, and by the different Parties hereto in separa o counterparts eac of whi ¢ h, en ex.ecuted shall be deemed to be an orig r)al but all of vhic,; � taken l ether sh - a I oo st � ute one and the same agreement. 8.14 Written Confirmation & SEC Compliance: MyRxWallet Prana Private Limited A subsidiary of MyRxWaUet North Am � c Corporation United Sl;i.tcs of America

(a) ormal Acknowledgment & Acceptance . The Seller shall provid a wr tt n confirmation or formal acceptance of 1 hi s Agr m nt � iltlin [7] busine$S c ys of execuUon. Such confirmation shall expressly acknO \ eclge f: at this Agreement is binding, enforceabla , and an nt grnl � rt of the transactiofl , {b) SEC S.1 In egration . Upon r'8C � lpl of th written confirmation, the Buyer shall have the right to Incorporate this Agreement Into its S - 1 Reg · stration Statement to notify the Securities and Exchange Commissioo (SEC) that th i s transaction ls pa of a planned Secondary Offering . svbjeci to market oondnions and regulatory approvats . (c} o Fu her Seller Approval R u i red . Tho Se l ler shall not unreasonably , · thhol , delay . Or' oondltlon such con ation e Seller 8(;:i(flO \ edges tha tho Buyer is under regulatory obligation to d i s - c lo e th s Agreement as pa of i s SEC registra Of'I process and agrees to cooperate i n good fai h . ARTICLE IX TERMINATION 1. T ermina � on Rights : This A9ree e n t may b tem,inated at any t i me under the follQwir \ g conditions : (a} M tual Term i nli.tlor,. By mu ual vriuen consent of both Buyer a'ld Se ll er vi 1 a priur vritten notice vit i n 15 days upon execu .i o " or t his SPA. {b) Any meteri I or non - rnEilar..a.l tang Ible or i tangibfe changes i mps ting the norm I business operations immedia ely upon ex u o of e Definitive Sha e Purchase Agreement shall oons · tute a Mate,lal Adverse Effect, quiring reasse sm nt of contractuaI obligations and may be subject to b r each of contractual agreemen '" (c) Failure to Satisfy Clo · i t � g Condltons . By cl er Buyer o r Se ll er • , the Closing Candltlons have not been satisfied by "Closing Dale \ uh le s s t1c falJure i due to e breach or f ilure of the party seeking termination . (d) Breach by Seller. By Buyer . if he S I brea es any mat · a1 rep r esentation , watranty , or oovonant and fails to cure such breach within 60 da)'$ aft r r lvmg ,vritten otice . ( � ) Rogu J atory Proh i bition . By either Buyer or Se ll er, 1r th nsactlon Is prohibited by law pr regulato, - y on.let from any appficab governmental authority . (f) Material Adverse Change . By B ye . If a Ma t e rl .:.1 1 Mvors o Change occurs t t negatively Impacts the finan ci al condition, b siness operations - , or a sets of the Seller before Closing . {g) Buyer's Non - Payrn nt. By Sell r If Buyer fail to deliver near t e Purchase ti O r' o her r qulr d con · dera ·on as agreed in this pur c hase agre,em nt. MyRxWallet Prana Private Limited A subsidiary of lllyRxWallet North America Corporation Unit d $t3tes ot AmerJc - a

9 . 2 Effoct of Termination : If this - Agreement is te rminate In SCOC>tdanoo with this section : (a) All obligations of the parties under this Agreament shall Immediately terminate , e oep tho e expressly stated to survive termina · on {e . g . , Confi entlality , Gover ing Law, Dispute Resolution). {b) lf terminaliot1 occurs due to a material breach , the non - breaching party shall have th right to pursue re edies available under law or e<i ity . {c) Any ful' \ ds, deposits, or escr � ed amounts shall be returned or d strlbuted in accordsnce , ll'l th& Agreement. /Signature page follows/ MyRxWallet Prana Private Limited A subsidiary of MyRJtW.illct North America Corporation United States of Amorlc �

IN WlTNESS WHEREOF. the parties hereto ave executed th i s Agra ment as oft e day and year first above written. ACQUIRER: Signature : _ Binh Do, Chief Financial Officer MyRxWallet North Arnerlca Corpora • n 24 75 South Jones Blvd, Suite 9 Las Vagas , NV 89146 Un i ted Sta es of America Email : binh@myrxwalle . app https;//nwtxwallet lo Phone � 408 . 797 . 8043 Dated : _ SELLER: � /:1•• l � Signa re: _, '1f_'"" "" _ Dr . P. Venkalesh Managing Director oah Therapeutics Pvt . Ltd . D.No . 7 - 1..645/A. Erragadtje, Sanath N gar Near Shilparamam, Madhapur Hyderabad, 500018 Telangana, lndi Email: venkal@noah erapeutlcs . co t https:// oah erapeu ics.com DIN : o 66 3C6 � 1 PAN : A,G, a Pp 3, 1 G c... L Phone : +91 - 9440383778 Dated : 19 A"" - " "'l - <> ,_ Signature: - � - ----- - Klshore K., Managing Director MyRxWallet Prana, Pvt. Ltd . 2475 South Jones Blvd, Su i te 9 Las Vegas, NV 89146 United States of America mail: klshore myrxwa lle1 . app https � //myrxwal let.io Mobile : 408 . 966.1400 Dated : 06.11712025 SELLER : Signature : r -- � - - � N.Upendra Di r ector Noah Therapeutics Pvt. Ltd. D . No . 7 - 1 - 645/A, Erragadda Senath Nagar, Near Shilparamam , Madhapur Hyderabad 1 500018 Telanga na, I d i a Email· upendra@noa therapeutics . co h. ps :/ /noahtherapeutics.com D I N : Cb , '5"5" 1 8 PAN : A I eN 6 ƒ 94 - N Phone : +91 - 9177 2445 Dated: 19 ': i t;, Cl .S 0.2.r MyRxWallet Prana Private Limited A subsJdlary of MyRxWallat North America Corporation Unlted States of America